Biotech company
DF9001 is being evaluated in adult patients for the treatment of advanced solid EGFR-positive tumours. It is being investigated as a monotherapy for non-small cell lung cancer, renal cell carcinoma and head and neck squamous cell carcinoma.
Dragonfly Therapeutics also shared that the treatment "potently redirects natural killer (NK) cells, gamma-delta T cells, and CD8 T cells by engaging activating receptors NKG2D and CD16".
Driving anti-tumour activity
We are hopeful that DF9001 in combination with KEYTRUDA will drive potent anti-tumour activity in a broad range of indications and are excited to further accelerate progress in the clinic to benefit patients in need”
“We are pleased to enter into this agreement with
"We are hopeful that DF9001 in combination with KEYTRUDA will drive potent anti-tumour activity in a broad range of indications and are excited to further accelerate progress in the clinic to benefit patients in need,” commented
It is anticipated that the first patients will be given Dragonfly’s EGFR immune engager and Merck’s anti-PD-1 therapy combination therapy for solid tumours in the final quarter of 2024.
Further details about the clinical trial for KEYTRUDA® (pembrolizumab) in combination with DF9001 can be found on clinicaltrials.gov: (NCT 05597839).
Last month, MSD (
The post MSD collaboration to drive development of solid tumour combination therapy appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source